85% — that is the rash rate of Revolution Medicines’ daraxonrasib at the 300 mg dose, and the number hanging over every patient and investor in the Pan-RAS inhibitor track.
Pan-RAS inhibitors, the breakthrough agents against the long “undruggable” target RAS, were meant to be a lifeline for patients with “king of cancers” such as pancreatic and colorectal cancer. Yet in exchange for covering a broader mutation spectrum, normal cells have paid the price.
Just as this track was beginning to see commercial light, a sudden patent storm caused Erasca’s market value to evaporate by billions of dollars in a single week, prompting the entire industry to re-examine: whose intellectual property is truly solid, and whose molecular design is truly original? Facing the dual test of toxicity and patents, the answer that Chinese biotech GenFleet Therapeutics has put forward may be quietly rewriting the global race.
The “Skin Predicament” of RAS Inhibitors
Pan-RAS inhibitors can simultaneously target the three RAS isoforms — KRAS, NRAS and HRAS — and in theory cover a broader patient population. But the flip side of the coin is that NRAS and HRAS proteins are widely expressed in normal human tissues, and non-selective inhibition of them will inevitably interfere with normal cellular physiology, triggering stronger toxicities — among which skin toxicity has become one of the most prominent clinical pain points.
Revolution Medicines’ daraxonrasib is a typical example of this dilemma. While it extended median OS in pancreatic cancer patients to 13.2 months, it also exposed serious skin toxicity: in its early phase 1/1b trial, the all-grade rash rate at the 300 mg dose reached 91%. In the phase 3 pivotal study RASolute 302 data presented at ASCO 2026, the all-grade rash rate was also as high as 85%.
Industry attention has turned to skin-toxicity management. At the AACR 2026 Annual Meeting, when Cogent Biosciences presented its Pan-KRAS(ON) inhibitor CGT1263, it explicitly listed “reducing the skin toxicity associated with multi-RAS inhibitors” as a differentiation target in its molecular design. This in itself suggests that skin-toxicity control is becoming one of the clinical-value elements pursued by the new generation of RAS inhibitors.
Faced with this industry-wide challenge of Pan-RAS toxicity, has GenFleet offered a differentiated solution?
GenFleet’s oral small-molecule Pan-RAS(ON) inhibitor GFH276 employs a unique tri-complex mechanism (CypA–GFH276–RAS), efficiently inhibiting most common, activated-state wild-type and mutant RAS proteins — not only covering common KRAS mutations (G12C, G12D, G12V, etc.), but also acting on NRAS and HRAS isoforms for broad target coverage. Preclinical data presented as a poster at the AACR 2025 Annual Meeting showed that, in multiple RAS-mutant tumor models, GFH276 demonstrated a lower efficacious dose and superior pharmacokinetic profile compared with overseas counterpart products, and in kinase-selectivity and safety-related target testing, GFH276 showed no activity at non-target targets — indicating good safety and target specificity.
Compared with daraxonrasib, in same-schedule oral dosing experiments, the tumor-inhibition effect achieved by daraxonrasib at 10 mg/kg QD was matched or exceeded by GFH276 at only 1 or 3 mg/kg QD. The substantial reduction in efficacious dose not only means an improvement in drug potency, but also means a reduction in systemic exposure — which is precisely the pharmacological basis for avoiding target-related safety toxicities, including skin toxicity.
In addition, GFH276’s unique mechanism gives it an additional advantage: compared with first-generation SIIP-binding KRAS inhibitors, GFH276 is expected to overcome the adaptive and acquired resistance limitations of existing agents. This means that, while differentiated on safety, it also has the potential to continue to play a role in different lines of therapy.
Another core product, GFH375, is an oral KRAS G12D (ON/OFF) inhibitor with good oral bioavailability, and has now entered the world’s first oral KRAS G12D inhibitor monotherapy phase 3 pivotal trial. Because the drug is a small molecule, it does not require CypA binding and does not interfere with HRAS/NRAS — so its off-target effects and mechanism-related toxicities are theoretically easier to control. Preclinical studies have shown that the tumor-growth inhibition effect of GFH375 monotherapy increased with dose and treatment duration, and that the drug showed low off-target risk in kinase-selectivity and safety-target testing.
Preliminary positive data from the U.S. phase 1/IIa study of GFH375 (VS-7375-101) showed that, in patients with previously treated advanced KRAS G12D-mutant solid tumors, GFH375 demonstrated anti-tumor activity, with no dose-limiting toxicities and no grade ≥1 gastrointestinal treatment-related adverse events (TRAEs).
The “Patent Storm” Around RAS Inhibitors
On April 24, 2026, Erasca received a letter from Revolution Medicines’ legal counsel. The letter contained three allegations: first, that Erasca’s pan-RAS molecular glue ERAS-0015 was “substantially equivalent” to the composition claimed in a RevMed-held U.S. patent (US Patent No. 12,409,225), constituting infringement under the doctrine of equivalents; second, that a third party had misappropriated RevMed’s alleged trade secrets when filing patents related to ERAS-0015, and that Erasca, as the licensee, bore responsibility; and third, that Erasca had improperly compared the preclinical data of ERAS-0015 with those of daraxonrasib in public disclosures, which RevMed considered “misleading statements.”
The reason this patent clash has drawn global industry attention is essentially the fierce competition on the RAS track. At present, neither Revolution Medicines’ nor Erasca’s RAS inhibitors have achieved product commercialization; under “first-come, first-served” track rules, seizing R&D and launch first-mover status is directly tied to corporate survival. More critically, Erasca was scheduled to release ERAS-0015’s phase 1 dose-escalation data on April 27, and the timing of the patent allegations undoubtedly delivered a precise blow.
On April 27, Erasca’s stock fell about 11% in a single day; on April 28, after disclosing that a 66-year-old pancreatic cancer patient had withdrawn from the clinical trial and died of severe pneumonia, the stock plunged another 48%, with market value evaporating by approximately USD 2.7 billion. Over the same period, Revolution Medicines’ stock rose about 8.8%, accumulating nearly 60% gains over a month. The rise and fall reflected the market’s high sensitivity to first-mover advantage and IP barriers on the RAS track.
In response to the allegations, Erasca’s management took a hard line, stating that it “firmly believes in its intellectual property,” considers Revolution Medicines’ allegations “groundless,”and will adopt an “active defense” stance. But regardless of the ultimate outcome of this patent dispute, it has already created substantial pressure on Erasca’s pipeline and stock performance.
In the face of this patent storm, GenFleet reacted quickly. On April 28, the company issued a statement clarifying and emphasizing that the entity, product and matters in dispute addressed in RevMed’s letter are all unrelated to GenFleet; that GenFleet’s GFH276 has fully independent, self-developed IP, and there is no risk of similar infringement or trade-secret disputes.
Behind this unequivocal statement lies GenFleet’s deep IP moat. Around its Pan-RAS inhibitor program, GenFleet has built a comprehensive global patent portfolio. The compound-structure patent for GFH276 was officially published on March 6, 2025, with protection expected to extend to 2044. According to the prospectus, GenFleet holds 72 granted patents and 118 pending patent applications, forming a comprehensive IP protection system covering compound structure, pharmaceutical composition, formulation and use.
More critically, GenFleet’s GFH276 uses a CypA–GFH276–RAS tri-complex mechanism, with distinctive originality in molecular structure. Although it belongs to the same technical class as Revolution Medicines’ daraxonrasib (a pan-RAS tri-complex molecular glue), the two differ significantly in specific molecular scaffold, binding mode and pharmacological properties.
In recent years, Chinese innovative-drug companies have repeatedly achieved overseas expansion through license-out deals, harvesting substantial upfront and milestone payments. But if the IP independence of a licensed product is in doubt, a patent challenge can not only affect the product’s overseas progress, but also leave both licensor and licensee in a passive position.
GenFleet’s Diversified Layout and Long-Term Potential
GenFleet has built a layered, differentiated pipeline matrix around the RAS signaling pathway. At the commercialized stage, GenFleet has fulzerasib , the first domestically approved KRAS G12C inhibitor, and is advancing its commercialization in China in partnership with Innovent Biologics.
At the same time, building on fulzerasib, GenFleet is further exploring its clinical value, addressing bypass activation in G12C-mutant tumors and advancing a fulzerasib plus cetuximab first-line NSCLC regimen — the world’s first KRAS + EGFR first-line combination therapy.
In the research pipeline, the KRAS G12D inhibitor GFH375 has entered phase 3, currently the most advanced oral KRAS G12D inhibitor in the world. The pan-RAS molecular glue GFH276 is in early-stage development and, by virtue of its differentiated safety design, has the potential to stand out among peer products.
At the same time, GenFleet is extending the boundary of RAS-targeted drugs toward macromolecular conjugated drugs. GFS784, developed on its proprietary FAScon platform, is the world’s first pan-RAS ADC to receive IND acceptance. It conjugates cetuximab to a pan-RAS molecular glue, and preclinical studies show that GFS784 inhibits both Dxd-loaded ADC-sensitive/-resistant tumors and osimertinib-resistant tumors.
Beyond the RAS track, GenFleet has also made differentiated deployments in cancer cachexia and autoimmune disease. Cachexia is a common, life-threatening wasting condition, and there is currently no FDA- or NMPA-approved drug specifically for cachexia — a huge unmet medical need.
GenFleet’s GFS202A is the world’s first cachexia bispecific to enter the clinic; it simultaneously targets GDF15 and IL-6 with high affinity, and through dual-target synergy is expected to further increase body weight, improve appetite and other cachexia-related symptoms/signs in cancer-cachexia patients. The drug is currently in a phase 1 trial in China; monotherapy in the first four dose cohorts showed excellent overall safety, with no dose-limiting toxicities (DLTs), treatment-related serious adverse events, or adverse events of special interest, and positive signals of post-dose weight gain and improved appetite have already been observed across multiple dose cohorts. Based on the potential value of the GDF15 and IL-6 pathways, GFS202A is expected to extend into IO-therapy sensitization, anti-heart-failure, and other indications, with a broad market outlook.
Relying on its multi-modality advanced platforms, GenFleet continues to produce new molecular entities for major indications, and expects to deliver 3–5 PCCs (from new molecular entity to IND-enabling stage) per year from 2026 onward. Several new drugs are currently in early-stage R&D, forming a complete development pipeline across multiple modalities: GFH009 is a highly selective CDK9 inhibitor for acute myeloid leukemia, with overseas rights licensed to SELLAS; GFH312 is a small-molecule RIPK1 inhibitor for peripheral arterial disease (with intermittent claudication), primary cholangitis, and other indications; GFH946 is an oral STAT6 degrader for autoimmune diseases.
Conclusion
GenFleet’s strength lies in the following: on the globally watched RAS track, it has not only achieved a 0-to-1 breakthrough, but has also established leading positions in multiple sub-directions. GenFleet’s pipeline story is, at its core, an innovation narrative centered on patients’ unmet clinical needs. As the “undruggable” barriers are broken down one by one, and as patients with “king of cancer”pancreatic cancer see new hope, this Chinese biotech is writing its own chapter of the era.